Yuen Wo Tsang
Chief Tech/Sci/R&D Officer at WAI YUEN TONG MEDICINE HOLDINGS LIMITED
Yuen Wo Tsang active positions
| Companies | Position | Start | End |
|---|---|---|---|
| WAI YUEN TONG MEDICINE HOLDINGS LIMITED | Chief Tech/Sci/R&D Officer | 01/09/2018 | - |
Luxembourg Institute of Health
 Luxembourg Institute of Health Miscellaneous Commercial ServicesCommercial Services Luxembourg Institute of Health (LIH) is an interdisciplinary research organization that focuses on identifying environmental, lifestyle, and behavioral factors affecting health. The private company is based in Strassen, Luxembourg. LIH uses its expertise in digital epidemiology, human biomonitoring, sport medicine, nutrition, and molecular biology to support the implementation and evaluation of new e-health technologies in the context of disease prevention and improving population health. Cancer is a priority disease for LIH, and Precision Oncology is at the heart of their efforts. The CEO of the Luxembourger company is Ulf Nehrbass. | Chief Tech/Sci/R&D Officer | - | - |
Career history of Yuen Wo Tsang
Training of Yuen Wo Tsang
| The University of Sydney | Graduate Degree |
| University of Aston | Undergraduate Degree |
Statistics
International
| Bermuda | 2 |
| Australia | 2 |
| United Kingdom | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| WAI YUEN TONG MEDICINE HOLDINGS LIMITED | Health Technology |
| Private companies | 1 |
|---|---|
Luxembourg Institute of Health
Luxembourg Institute of Health Miscellaneous Commercial ServicesCommercial Services Luxembourg Institute of Health (LIH) is an interdisciplinary research organization that focuses on identifying environmental, lifestyle, and behavioral factors affecting health. The private company is based in Strassen, Luxembourg. LIH uses its expertise in digital epidemiology, human biomonitoring, sport medicine, nutrition, and molecular biology to support the implementation and evaluation of new e-health technologies in the context of disease prevention and improving population health. Cancer is a priority disease for LIH, and Precision Oncology is at the heart of their efforts. The CEO of the Luxembourger company is Ulf Nehrbass. | Commercial Services |
- Stock Market
- Insiders
- Yuen Wo Tsang
- Experience
